Ypsomed Holding Ag · SIX:YPSN

Ypsomed — H1 2025/26 Earnings Presentation

36 slides from Ypsomed's earnings presentation, Nov 12, 2025

  1. Slide 1: Ypsomed Half Year Results 2025/26

    Ypsomed Half Year Results 2025/26 Transforming selfcare, Transforming Ypsomed Webcast, 12 November 2025

  2. Slide 2: Important information

    Important information The information contained in this document has not been verified by an independent source. It should be taken with caution, and no assurance or guarantee is given (either explicit or implied) regarding the fairness, accuracy, completeness or correctness of the information or op

  3. Slide 3: Our purpose is to make selfcare simpler and easier

    Our purpose is to make selfcare simpler and easier 3 | Ypsomed Holding AG | Half year results 2025/26 PUBLIC

  4. Slide 4: Ypsomed benefits from structural growth drivers

    Ypsomed benefits from structural growth drivers 4 | Ypsomed Holding AG | Half year results 2025/26 PUBLIC

  5. Slide 5: Clear strategic focus and solid structure position Ypsomed to benefit from end market growth

    Thanks to its clear strategic focus and solid structure, Ypsomed is uniquely positioned to benefit from significant growth in the end market Pure-play Innovation Operational Strong injection leadership excellence financials specialist 5 | Ypsomed Holding AG | Half year results 2025/26 PUBLIC

  6. Slide 6: Ypsomed is a pure-play injection specialist

    Ypsomed is a pure-play injection specialist Pure-play Innovation Operational Strong injection leadership excellence financials specialist 6 | Ypsomed Holding AG | Half year results 2025/26 PUBLIC

  7. Slide 7: Ypsomed has completed its transformational journey to a pure-play self-injection specialist

    Ypsomed has completed its transformational journey to become a pure-play self-injection specialist Ypsomed is now a pure play self-injection specialist 2025 Completion of the sale of Ypsotec 2025 Completion of the sale of the diabetes care business 2024 Completion of the sale of the pen needle and B

  8. Slide 8: Delivery Systems generated revenue of CHF 267 million in first half 2025/26

    Ypsomed’s new starting point – Delivery Systems generated revenue of CHF 267 million in the first half of the financial year 2025/26 Revenue contribution Revenue contribution HY 2025/26 (in mCHF) mid-term 21 75 Delivery Systems 267 Diabetes Care Other 8 | Ypsomed Holding AG | Half year results 2025/

  9. Slide 9: Ypsomed is a leader in the innovation of delivery systems

    Ypsomed is a leader in the innovation of delivery systems Pure-play Innovation Operational Strong injection leadership excellence financials specialist 9 | Ypsomed Holding AG | Half year results 2025/26 PUBLIC

  10. Slide 10: Ypsomed has the widest range of self-injection solutions on the market

    Ypsomed has the widest range of self-injection solutions on the market 10 | Ypsomed Holding AG | Half year results 2025/26 PUBLIC

  11. Slide 11: SmartPilot received 510(k) approval for the U.S. market in September

    Our SmartPilot received the 510(k) approval for the U.S. Market in September 11 | Ypsomed Holding AG | Half year results 2025/26 PUBLIC

  12. Slide 12: Three new device platforms in 2025; YpsoLoop wins CPHI Innovation Award

    We announced three new devices platforms in 2025, and won the CPHI Innovation Award with the new YpsoLoop autoinjector platform YpsoLoop Winner of CPHI Innovation Award 12 | Ypsomed Holding AG | Half year results 2025/26 PUBLIC

  13. Slide 13: New platforms will have a significantly lower carbon footprint

    Ypsomed’s new platforms will have a significantly lower carbon footprint Stepwise carbon footprint reduction g CO2-equivalents per device –22% -45% +52% –64%  NetZero program: replacement of the majority of current materials with bio- based but chemically identical materials 234  YpsoLoop: new eco

  14. Slide 14: New product launches in incretin and Alzheimer therapies

    Ypsomed launched new products in high-value, first-in-class incretin and Alzheimer therapies Launch highlights in HY 2025/26  First dual-agonist incretin therapy launched in the Chinese market  Launch of ground-breaking Alzheimer medication in YpsoMate 2.25 ml  Innovative autoimmune therapy for J

  15. Slide 15: Diversified customer base with no customer exceeding 15% of revenue

    Ypsomed has a diversified customer base with no customer exceeding 15% of revenue currently and in the foreseeable future… Commercial sales by customer HY 2025/26 Balanced customer exposure Illustrative, YDS only  >130 customers of which ~30 in incretins  No customer contributes >15% of commercial

  16. Slide 16: More than 70 approved therapies in various therapeutic areas

    … and supports patients with more than 70 approved therapies in various therapeutic areas Pens Autoinjectors  Obesity  Diabetes  Asthma  Oncology  Fertility  Alzheimer  Osteoporosis 70+  Growth Disorders  Obesity  Atopic Dermatitis  ATTR Amyloidosis  Psoriasis  Rheumatoid Arthritis Prod

  17. Slide 17: Ypsomed wins through service excellence and customer centricity

    Beyond innovation, Ypsomed wins in the market thanks to service excellence and customer centricity 17 | Ypsomed Holding AG | Half year results 2025/26 PUBLIC

  18. Slide 18: Ypsomed has a strong focus on operational excellence

    Ypsomed has a strong focus on operational excellence Pure-play Innovation Operational Strong injection leadership excellence financials specialist 18 | Ypsomed Holding AG | Half year results 2025/26 PUBLIC

  19. Slide 19: Expanding local for local to install 1 billion devices capacity

    We are expanding local for local, to install 1 billion devices capacity by the beginning of the next decade Installed capacity beginning of next decade Illustrative 1 billion devices CH (Solothurn / Burgdorf) CN (Changzhou) DE (Schwerin) US (Holly Springs) 19 | Ypsomed Holding AG | Half year results

  20. Slide 20: Ypsomed builds a global manufacturing footprint

    Ypsomed builds a global manufacturing footprint, producing local for local Holly Springs Schwerin (D) Schwerin II (D) opening 2027 opening 2026 Burgdorf HQ (CH) Solothurn (CH) Burgdorf (CH) Burgdorf (CH) Suzhou (CN) Changzhou (CN) (Contract Manufacturer) 20 | Ypsomed Holding AG | Half year results 2

  21. Slide 21: US expansion accelerated with site selected in Holly Springs, North Carolina

    We accelerated our timeline to expand to the US with a brown-field site selected in Holly Springs, North Carolina to open in Q4 2027 21 | Ypsomed Holding AG | Half year results 2025/26 PUBLIC

  22. Slide 22: First production site opened in Changzhou, China in June 2025

    Ypsomed opened first production site in Changzhou in China in June 2025 22 | Ypsomed Holding AG | Half year results 2025/26 PUBLIC

  23. Slide 23: Topping-out ceremony for Schwerin 2 in October 2025

    We celebrated the topping-out ceremony for Schwerin 2 in October 2025 23 | Ypsomed Holding AG | Half year results 2025/26 PUBLIC

  24. Slide 24: Topping-out ceremony for Schwerin 2 in October 2025

    We celebrated the topping-out ceremony for Schwerin 2 in October 2025 24 | Ypsomed Holding AG | Half year results 2025/26 PUBLIC

  25. Slide 25: Phasing out Contract Manufacturing YDS in Solothurn

    In Solothurn we are phasing out Contract Manufacturing YDS to focus on proprietary autoinjectors until end of 2026 25 | Ypsomed Holding AG | Half year results 2025/26 PUBLIC

  26. Slide 26: Number of employees

    Ypsomed created 189 jobs globally in HY 2025/26, thereof 45 in Switzerland – 780 employees moved to TecMed with YDC carve-out 2 753 744 2 753 2 389 641 2 162 2 162 Ypsotec 2 059 Diabetes Care Number of employees 2 011 Delivery Systems 1 854 791 752 Abroad production and R&D 939 569 687 Abroad sales

  27. Slide 27: Ypsomed has a strong and robust financial position

    Ypsomed has a strong and robust financial position Pureplay Innovation Operational Strong injection leadership excellence financials specialist 27 | Ypsomed Holding AG | Half year results 2025/26 PUBLIC

  28. Slide 28: Revenue of CHF 267 million in Delivery Systems business

    Revenue of CHF 267 million in Delivery Systems business Revenue Ypsomed Group Total Revenue breakdown HY 2025/26 Revenue drivers  Overall Ypsomed group delivered 21 revenue of CHF 363 million 75  4 months of YDC revenue reported (until Closing in July 2025)  “Other” includes Diabetes Care Contrac

  29. Slide 29: Growth of 21% in core business Delivery Systems

    Growth of 21% in core business Delivery Systems Revenue Ypsomed Delivery Systems 52 267 43 220 Growth trajectory  Project revenue growth of 20% indicating strong pipeline for commercial projects in million CHF 215  Above average commercial sales growth 177 Project Revenue of 46% for autoinjectors

  30. Slide 30: EBIT of CHF 152 million reported; Delivery Systems EBIT

    EBIT of CHF 87 million in continued Delivery Systems business EBIT Ypsomed Group 152 EBIT drivers 70 -5  32.4% EBIT margin for Delivery Systems 87  Other includes a book profit of CHF 74.6 in million CHF million from Diabetes Care divestment YDC YDS HY 2025/26 EBIT reported Other 30 | Ypsomed Hold

  31. Slide 31: Growth investments in infrastructure and R&D

    CHF 146 million growth investments in infrastructure and R&D Investments Ypsomed Group 20 146 138 Fixed assets  Expansion of operating infrastructure in 39 Schwerin (DE), Solothurn (CH) and Changzhou (CN) in million CHF 126 Intangible assets 99 Intangible Assets  Future pen and autoinjector platfo

  32. Slide 32: Proceeds of sale from YDC lead to net-neutral cash flow

    Proceeds of sale from YDC lead to net-neutral cash flow Cash flow Ypsomed Group Cash flow  Strong cash flow (CF) from operating 157 activities  Repeated rise in investments in capacity 287 288 in million CHF expansions vs HY 2024/25 130  Proceeds of sale of YDC business used to finance CAPEX and

  33. Slide 33: Creating value and maintaining a solid balance sheet

    Creating value and maintaining a solid balance sheet  We achieved a ROCE of around 21% in the core business (YDS)  Net debt / EBITDA (from continuing operations of the last 12 months) decreased to 0.3x  Ypsomed therefore continues to have a very solid balance sheet and can finance future organic

  34. Slide 34: We confirm our Guidance for FY 2025/26

    We confirm our Guidance for FY 2025/26  Ypsomed confirms its expectation to reach a revenue growth of around 20% and an EBIT between CHF 190 and 210 million in the continued Delivery Systems business for the 2025/26 financial year. 34 | Ypsomed Holding AG | Half year results 2025/26 PUBLIC

  35. Slide 35: Ypsomed is set to continue to grow significantly

    Ypsomed is set to continue to grow significantly Net Sales Mid-term ambition (FY 2029/30) Illustrative  CHF 0.9 − 1.1 billion sales in Delivery Systems  CHF 280 − 340 million EBIT (not less than 30% EBIT margin) Note: Graph is purely conceptual to outline trends  Stable ROCE (~20%) (all years) 20

  36. Slide 36: We look forward to your questions.

    We look forward to your questions.

Ypsomed Holding — H1 2025/26 Earnings Presentation on 6ix